Loading...

K&K Herbal Poland

WSE:KKH
Snowflake Description

Excellent balance sheet and fair value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
KKH
WSE
PLN1M
Market Cap
  1. Home
  2. PL
  3. Retail
Company description

K&K Herbal Poland S.A. primarily focuses on the distribution and sale of dietary supplements and cosmetics, medical devices, and veterinary products in Poland. The last earnings update was 93 days ago. More info.


Add to Portfolio Compare Print
KKH Share Price and Events
7 Day Returns
-1.3%
WSE:KKH
1.1%
PL Retail Distributors
-0.9%
PL Market
1 Year Returns
-22.6%
WSE:KKH
-18%
PL Retail Distributors
-7.4%
PL Market
KKH Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
K&K Herbal Poland (KKH) -1.3% -2% -8.1% -22.6% -55.5% -54.1%
PL Retail Distributors 1.1% -9% -4.8% -18% -26% 5.6%
PL Market -0.9% -7.5% -6.6% -7.4% 9.6% -11.5%
1 Year Return vs Industry and Market
  • KKH underperformed the Retail Distributors industry which returned -18% over the past year.
  • KKH underperformed the Market in Poland which returned -7.4% over the past year.
Price Volatility
KKH
Industry
5yr Volatility vs Market

KKH Value

 Is K&K Herbal Poland undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of K&K Herbal Poland to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for K&K Herbal Poland.

WSE:KKH Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Extrapolated from most recent financials. See below
Discount Rate (Cost of Equity) See below 9.1%
Perpetual Growth Rate 10-Year PL Government Bond Rate 2.9%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for WSE:KKH
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year PL Govt Bond Rate 2.9%
Equity Risk Premium S&P Global 7.1%
Retail Distributors Unlevered Beta Simply Wall St/ S&P Global 0.82
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.819 (1 + (1- 19%) (0.78%))
0.882
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.88
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.85% + (0.882 * 7.14%)
9.15%

Discounted Cash Flow Calculation for WSE:KKH using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for K&K Herbal Poland is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

WSE:KKH DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (PLN, Millions) Source Present Value
Discounted (@ 9.15%)
2019 0.67 Est @ 78.27% 0.62
2020 1.05 Est @ 55.64% 0.88
2021 1.46 Est @ 39.8% 1.13
2022 1.88 Est @ 28.72% 1.33
2023 2.28 Est @ 20.96% 1.47
2024 2.63 Est @ 15.53% 1.56
2025 2.94 Est @ 11.72% 1.59
2026 3.21 Est @ 9.06% 1.59
2027 3.44 Est @ 7.2% 1.56
2028 3.64 Est @ 5.89% 1.52
Present value of next 10 years cash flows PLN13.24
WSE:KKH DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= PLN3.64 × (1 + 2.85%) ÷ (9.15% – 2.85%)
PLN59.46
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= PLN59.46 ÷ (1 + 9.15%)10
PLN24.78
WSE:KKH Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= PLN13.24 + PLN24.78
PLN38.02
Equity Value per Share
(PLN)
= Total value / Shares Outstanding
= PLN38.02 / 7.41
PLN5.13
WSE:KKH Discount to Share Price
Calculation Result
Value per share (PLN) From above. PLN5.13
Current discount Discount to share price of PLN0.15
= -1 x (PLN0.15 - PLN5.13) / PLN5.13
97.1%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price K&K Herbal Poland is available for.
Intrinsic value
>50%
Share price is PLN0.15 vs Future cash flow value of PLN5.13
Current Discount Checks
For K&K Herbal Poland to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • K&K Herbal Poland's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • K&K Herbal Poland's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for K&K Herbal Poland's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are K&K Herbal Poland's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
WSE:KKH PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in PLN PLN0.00
WSE:KKH Share Price ** WSE (2019-05-17) in PLN PLN0.15
Poland Retail Distributors Industry PE Ratio Median Figure of 6 Publicly-Listed Retail Distributors Companies 13.7x
Poland Market PE Ratio Median Figure of 462 Publicly-Listed Companies 10.69x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of K&K Herbal Poland.

WSE:KKH PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= WSE:KKH Share Price ÷ EPS (both in PLN)

= 0.15 ÷ 0.00

-94.66x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • K&K Herbal Poland is loss making, we can't compare its value to the PL Retail Distributors industry average.
  • K&K Herbal Poland is loss making, we can't compare the value of its earnings to the Poland market.
Price based on expected Growth
Does K&K Herbal Poland's expected growth come at a high price?
Raw Data
WSE:KKH PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -94.66x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Retail Distributors Industry PEG Ratio Median Figure of 7 Publicly-Listed Retail Distributors Companies 1.06x
Poland Market PEG Ratio Median Figure of 113 Publicly-Listed Companies 0.93x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for K&K Herbal Poland, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on K&K Herbal Poland's assets?
Raw Data
WSE:KKH PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in PLN PLN0.19
WSE:KKH Share Price * WSE (2019-05-17) in PLN PLN0.15
Poland Retail Distributors Industry PB Ratio Median Figure of 8 Publicly-Listed Retail Distributors Companies 1.35x
Poland Market PB Ratio Median Figure of 688 Publicly-Listed Companies 0.97x
WSE:KKH PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= WSE:KKH Share Price ÷ Book Value per Share (both in PLN)

= 0.15 ÷ 0.19

0.76x

* Primary Listing of K&K Herbal Poland.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • K&K Herbal Poland is good value based on assets compared to the PL Retail Distributors industry average.
X
Value checks
We assess K&K Herbal Poland's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Retail Distributors industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Retail Distributors industry average (and greater than 0)? (1 check)
  5. K&K Herbal Poland has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

KKH Future Performance

 How is K&K Herbal Poland expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as K&K Herbal Poland has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
11.3%
Expected Retail Distributors industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is K&K Herbal Poland expected to grow at an attractive rate?
  • Unable to compare K&K Herbal Poland's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare K&K Herbal Poland's earnings growth to the Poland market average as no estimate data is available.
  • Unable to compare K&K Herbal Poland's revenue growth to the Poland market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
WSE:KKH Future Growth Rates Data Sources
Data Point Source Value (per year)
Poland Retail Distributors Industry Earnings Growth Rate Market Cap Weighted Average 11.3%
Europe Retail Distributors Industry Revenue Growth Rate Market Cap Weighted Average 1.8%
Poland Market Earnings Growth Rate Market Cap Weighted Average 10%
Poland Market Revenue Growth Rate Market Cap Weighted Average 5.5%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
WSE:KKH Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in PLN Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
WSE:KKH Past Financials Data
Date (Data in PLN Millions) Revenue Cash Flow Net Income *
2018-12-31 2 0 0
2018-09-30 2 0 0
2018-06-30 1 0 0
2018-03-31 2 0 0
2017-12-31 2 0 0
2017-09-30 2 0 0
2017-06-30 2 0 0
2017-03-31 2 0 0
2016-12-31 2 0 0
2016-09-30 2 0 0
2016-06-30 2 0 0
2016-03-31 1 0 0

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if K&K Herbal Poland is high growth as no earnings estimate data is available.
  • Unable to determine if K&K Herbal Poland is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
WSE:KKH Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from K&K Herbal Poland Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

WSE:KKH Past Financials Data
Date (Data in PLN Millions) EPS *
2018-12-31 0.00
2018-09-30 0.00
2018-06-30 0.00
2018-03-31 0.00
2017-12-31 0.00
2017-09-30 0.00
2017-06-30 0.00
2017-03-31 -0.01
2016-12-31 -0.01
2016-09-30 0.00
2016-06-30 0.02
2016-03-31 0.02

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if K&K Herbal Poland will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine whether K&K Herbal Poland is trading at K&K Herbal Poland'san attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
  2. K&K Herbal Poland's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Retail companies here
  3. K&K Herbal Poland's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess K&K Herbal Poland's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Poland market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
K&K Herbal Poland has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

KKH Past Performance

  How has K&K Herbal Poland performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare K&K Herbal Poland's growth in the last year to its industry (Retail Distributors).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • K&K Herbal Poland does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare K&K Herbal Poland's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare K&K Herbal Poland's 1-year growth to the PL Retail Distributors industry average as it is not currently profitable.
Earnings and Revenue History
K&K Herbal Poland's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from K&K Herbal Poland Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

WSE:KKH Past Revenue, Cash Flow and Net Income Data
Date (Data in PLN Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 1.52 -0.01 0.55
2018-09-30 1.53 -0.01 0.54
2018-06-30 1.39 -0.03 0.53
2018-03-31 1.53 0.02 0.56
2017-12-31 1.53 0.00 0.59
2017-09-30 1.79 0.03 0.61
2017-06-30 1.95 -0.03 0.65
2017-03-31 1.90 -0.04 0.62
2016-12-31 1.78 -0.03 0.58
2016-09-30 1.58 -0.02 0.54
2016-06-30 1.53 0.07 0.48
2016-03-31 1.45 0.08 0.49
2015-12-31 1.46 0.07 0.47
2015-09-30 1.31 0.06 0.43
2015-06-30 1.25 0.06 0.40
2015-03-31 1.29 0.06 0.38
2014-12-31 1.28 0.05 0.39
2014-09-30 1.24 0.07 0.40
2014-06-30 1.14 0.05 0.38
2014-03-31 0.95 0.04 0.34
2013-12-31 0.82 0.04 0.30
2013-09-30 0.71 0.05 0.49
2013-06-30 0.73 0.07 0.42
2013-03-31 0.80 0.10 0.35
2012-12-31 0.83 0.10 0.28
2012-09-30 0.91 0.08 0.22
2012-06-30 0.93 0.06 0.22

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if K&K Herbal Poland has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if K&K Herbal Poland has efficiently used its assets last year compared to the PL Retail Distributors industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if K&K Herbal Poland improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess K&K Herbal Poland's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Retail Distributors industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
K&K Herbal Poland has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

KKH Health

 How is K&K Herbal Poland's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up K&K Herbal Poland's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • K&K Herbal Poland is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • K&K Herbal Poland's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of K&K Herbal Poland's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 151.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from K&K Herbal Poland Company Filings, last reported 4 months ago.

WSE:KKH Past Debt and Equity Data
Date (Data in PLN Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 1.42 0.01 0.68
2018-09-30 1.45 0.00 0.33
2018-06-30 1.45 0.00 0.12
2018-03-31 1.46 0.00 0.28
2017-12-31 1.44 0.01 0.30
2017-09-30 1.46 0.00 0.57
2017-06-30 1.48 0.00 0.47
2017-03-31 1.11 0.01 0.43
2016-12-31 1.10 0.00 0.24
2016-09-30 1.09 0.02 0.34
2016-06-30 1.17 0.02 0.24
2016-03-31 1.15 0.00 0.34
2015-12-31 1.13 0.02 0.43
2015-09-30 1.11 0.02 0.44
2015-06-30 1.10 0.02 0.30
2015-03-31 0.85 0.06 0.31
2014-12-31 0.84 0.03 0.32
2014-09-30 0.83 0.03 0.20
2014-06-30 0.82 0.04 0.21
2014-03-31 0.79 0.04 0.31
2013-12-31 0.79 0.04 0.30
2013-09-30
2013-06-30
2013-03-31
2012-12-31 0.57 0.11 0.00
2012-09-30
2012-06-30
  • K&K Herbal Poland's level of debt (0.6%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (5.2% vs 0.6% today).
  • Debt is well covered by operating cash flow (4907.5%, greater than 20% of total debt).
  • K&K Herbal Poland is making a loss, therefore interest payments are not well covered by earnings.
X
Financial health checks
We assess K&K Herbal Poland's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. K&K Herbal Poland has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

KKH Dividends

 What is K&K Herbal Poland's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from K&K Herbal Poland dividends.
If you bought PLN2,000 of K&K Herbal Poland shares you are expected to receive PLN0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate K&K Herbal Poland's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate K&K Herbal Poland's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
WSE:KKH Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Poland Retail Distributors Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 0.5%
Poland Market Average Dividend Yield Market Cap Weighted Average of 201 Stocks 4.1%
Poland Minimum Threshold Dividend Yield 10th Percentile 1.5%
Poland Bottom 25% Dividend Yield 25th Percentile 2.8%
Poland Top 25% Dividend Yield 75th Percentile 7.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as K&K Herbal Poland has not reported any payouts.
  • Unable to verify if K&K Herbal Poland's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of K&K Herbal Poland's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as K&K Herbal Poland has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess K&K Herbal Poland's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.5%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can K&K Herbal Poland afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. K&K Herbal Poland has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

KKH Management

 What is the CEO of K&K Herbal Poland's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Krzysztof Milaszewski
CEO Bio

Mr. Krzysztof Milaszewski serves as Chairman of The Management Board at K&K Herbal Poland Spólka Akcyjna.

CEO Compensation
  • Insufficient data for Krzysztof to compare compensation growth.
  • Insufficient data for Krzysztof to establish whether their remuneration is reasonable compared to companies of similar size in Poland.
Management Team

Krzysztof Milaszewski

TITLE
Chairman of the Management Board
Board of Directors

Jacek Grzyb

TITLE
Chairman of the Supervisory Board

Irena Milaszewska

TITLE
Vice Chairman of the Supervisory Board

Sylwia Blasiak

TITLE
Member of the Supervisory Board

Krzysztof Sienicki

TITLE
Member of the Supervisory Board

Bogdan Lizak

TITLE
Member of the Supervisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (PLN) Value (PLN)
X
Management checks
We assess K&K Herbal Poland's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. K&K Herbal Poland has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

KKH News

Simply Wall St News

How Much Of K&K Herbal Poland S.A. (WSE:KKH) Do Insiders Own?

Every investor in K&K Herbal Poland S.A. … As Nassim Nicholas Taleb said, 'Don’t tell me what you think, tell me what you have in your portfolio.'. … View our latest analysis for K&K Herbal Poland

Simply Wall St -

Does Market Volatility Impact K&K Herbal Poland S.A.'s (WSE:KKH) Share Price?

Volatility is considered to be a measure of risk in modern finance theory. … Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). … Any stock with a beta of greater than one is considered more volatile than the market, while those with a beta below one are either less volatile or poorly correlated with the market.

Simply Wall St -

What Percentage Of K&K Herbal Poland S.A. (WSE:KKH) Shares Do Insiders Own?

K&K Herbal Poland is not a large company by global standards. … Our analysis of the ownership of the company, below, shows that. … Check out our latest analysis for K&K Herbal Poland

Simply Wall St -

Before You Buy K&K Herbal Poland SA (WSE:KKH), Consider Its Volatility

If you're interested in K&K Herbal Poland SA (WSE:KKH), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. … Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility). … While we should keep in mind that Warren Buffett has cautioned that 'Volatility is far from synonymous with risk', beta is still a useful factor to consider.

Simply Wall St -

How Has K&K Herbal Poland SA's (WSE:KKH) Earnings Fared Against The Long Term Trend

In this article, I will take a look at K&K Herbal Poland SA's (WSE:KKH) track record on a high level, to give you some insight into how the company has been performing against its historical trend and its industry peers. … Have KKH's earnings improved against past performances and the industry … KKH's trailing twelve-month earnings (from 31 March 2018) of zł18.0k has

Simply Wall St -

Should You Be Tempted To Sell K&K Herbal Poland SA (WSE:KKH) At Its Current PE Ratio?

K&K Herbal Poland SA (WSE:KKH) is trading with a trailing P/E of 70x, which is higher than the industry average of 14.5x. … Although some investors may jump to the conclusion that you should avoid the stock or sell if you own it, understanding the assumptions behind the P/E ratio might change your mind. … I will explain what the P/E ratio is as well as what you should look out for when using it

Simply Wall St -

Should You Have K&K Herbal Poland SA's (WSE:KKH) In Your Portfolio?

Generally, an investor should consider two types of risk that impact the market value of KKH. … The second type is market risk, one that you cannot diversify away, since it arises from macroeconomic factors which directly affects all the stocks in the market. … A widely-used metric to measure a stock's market risk is beta, and the broad market index represents a beta value of one.

Simply Wall St -

With An ROE Of 1.23%, Can K&K Herbal Poland SA (WSE:KKH) Catch Up To The Industry?

This analysis is intended to introduce important early concepts to people who are starting to invest. … and want to better understand how you can grow your money by investing in K&K Herbal Poland SA (WSE:KKH). … K&K Herbal Poland SA (WSE:KKH) delivered a less impressive 1.23% ROE over the past year, compared to the 12.47% return generated by its industry.

Simply Wall St -

Does K&K Herbal Poland SA. (WSE:KKH)'s Capital Return Make The Cut?

To understand K&K Herbal Poland’s capital returns we will look at a useful metric called return on capital employed. … I have calculated K&K Herbal Poland’s ROCE for you below: ROCE Calculation for KKH Return on Capital Employed (ROCE) = Earnings Before Tax (EBT) ÷ (Capital Employed) Capital Employed = (Total Assets - Current Liabilities) ∴ ROCE = ZŁ3.64K ÷ (ZŁ1.59M - ZŁ148.05K) = 0.25% KKH’s 0.25% ROCE means that for every PLN100 you invest, the company creates PLN0.3. … K&K Herbal Poland's relatively poor ROCE is tied to the movement in two factors that change over time: earnings and capital requirements.

Simply Wall St -

Who Are The Largest Shareholders In K&K Herbal Poland SA. (WSE:KKH)?

In this analysis, my focus will be on developing a perspective on K&K Herbal Poland SA.’s (WSE:KKH) latest ownership structure, a less discussed, but important factor. … A company's ownership structure is often linked to its share performance in both the long- and short-term. … View our latest analysis for K&K Herbal Poland WSE:KKH Ownership_summary Apr 20th 18 Insider Ownership Insiders form another group of important ownership types as they manage the company's operations and decide the best use of capital.

Simply Wall St -

KKH Company Info

Description

K&K Herbal Poland S.A. primarily focuses on the distribution and sale of dietary supplements and cosmetics, medical devices, and veterinary products in Poland. The company provides EnteFace, a face mask cleaner; Enterosgel, a medical device; and contactless thermometer, such as SYNERGICA SG1000. It offers its medical devices under the SYNERGICA brand. The company sells its products through pharmaceutical wholesalers, pharmacies, medical and herbal shops, and other partners, as well as through online stores. K&K Herbal Poland S.A. is based in Wieliczka, Poland.

Details
Name: K&K Herbal Poland S.A.
KKH
Exchange: WSE
Founded:
PLN1,088,640
7,405,718
Website: http://kkpoland.pl
Address: K&K Herbal Poland S.A.
ul. Limanowskiego 1A lok. 8,
Wieliczka,
32-020,
Poland
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
WSE KKH Common Bearer Shares Warsaw Stock Exchange PL PLN 17. Jul 2012
Number of employees
Current staff
Staff numbers
0
K&K Herbal Poland employees.
Industry
Distributors
Retail
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/18 22:00
End of day share price update: 2019/05/17 00:00
Last earnings filing: 2019/02/14
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.